Plain-English translation of NCT06157996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding lenvatinib to a combination of tislelizumab and chemotherapy (called CapeOX) helps people with advanced stomach cancer live longer and stay disease-free longer. The study will compare the three-drug combination to the two-drug combination alone in about 92 patients whose tumors have specific characteristics that might make this treatment work better.
Standard treatments for advanced stomach cancer don't work well enough for everyone, and doctors want to see if adding this medication to improve how the body's immune system fights cancer could help patients live longer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the three-drug combination or the two-drug combination. Treatment happens in 3-week cycles, with intravenous infusions and oral pills taken at home, for up to 8 cycles. After that, you'll continue with maintenance therapy. You'll have follow-up appointments every 9 weeks (with scans and blood tests) to check how well the treatment is working, continuing until your cancer progresses, you experience severe side effects, or you've completed the study protocol.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China